Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Rakovina Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Rakovina Therapeutics Expands Strategic Collaborations to Support AI Research
Details : The collaboration aims to synthesize novel lead drug candidates identified by the Deep Docking AI platform for further validation, with Rakovina Therapeutics owning rights to developed molecules.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
May 08, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Rakovina Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?